ChartRow logo
Data provided bySource: Twelve Data
NBIX
$165.92+0.37%
as of close, Nov 17, 2026
☾ AH $165.92 +0.37%
Share this page

NBIX financial statements

The full income statement, balance sheet, and cash-flow statement for Neurocrine Biosciences Inc. (NBIX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

5Y CAGR +22.3%10Y CAGR +64.5%YoY +41.2%
$3.7B TTM$1.1B Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Gross profit

5Y CAGR +22.1%10Y CAGR +64.2%YoY +42.1%
$2.8B FY25— Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR +30.6%10Y n/mYoY +38.6%
$887.1M TTM$331.3M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR +3.3%10Y n/mYoY −1.4%
$702.5M TTM$206.5M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR +2.3%10Y n/mYoY −3.9%
$6.74 TTM$1.96 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating cash flow

5Y CAGR +27.9%10Y n/mYoY +73.7%
$1.1B TTM$395.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Capital expenditure

5Y CAGR +25.5%10Y CAGR +33.2%YoY −12.1%
$26.1M TTM$11.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR +28.0%10Y n/mYoY +79.0%
$1B TTM$383.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Shares (diluted)

5Y +4.8%10Y +21.3%YoY +2.6%
104.2M TTM105.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Every NBIX chart on Trends →

Shares outstanding (point-in-time)

2024-09 101.2M2024-12 99.7M2025-03 99.0M2025-06 99.2M2025-09 99.7M2025-12 100.4M2026-03 100.5M2026-06 101.6M2026-09 101.2M-0.0% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Revenue2.86B+21.4%2.36B+24.8%1.89B+26.8%1.49B+31.3%1.13B+8.4%
2.81B+21.0%2.32B+25.7%1.85B+26.1%1.47B+30.9%1.12B+8.1%
Cost of revenue52.1M+53.2%34.0M-14.4%39.7M+71.1%23.2M+62.2%14.3M+41.6%
————1.03B+16.8%
Research & development1.02B+38.9%731M+29.4%565M+21.8%464M+41.4%328M+19.3%
Selling, general & administrative1.16B+14.8%1.01B+13.5%888M+17.9%753M+29.0%583M+34.6%
Amortization of intangibles4.10M+13.9%3.60M+2.9%3.50M+600.0%500K0.00
Operating income619M+8.5%571M+127.4%251M+0.8%249M+142.9%103M-37.1%
Interest expense——4.60M-35.2%7.10M-72.5%25.8M-21.3%
Other non-operating income86.3M+202.1%-84.5M-204.1%81.2M+331.3%-35.1M-3090.9%-1.10M+98.0%
Gain (loss) on equity securities-4.00M+89.2%-37.1M-230.6%28.4M-7.8%30.8M+47.4%20.9M+218.1%
Pre-tax income705M+45.1%486M+46.3%332M+55.3%214M+110.9%101M-5.0%
Income tax227M+56.7%145M+75.6%82.4M+38.7%59.4M+403.4%11.8M+103.9%
479M+40.2%341M+36.7%250M+61.6%155M+72.4%89.6M-78.0%
Net income to common479M+40.2%341M+36.7%250M+61.6%155M+72.4%89.6M-78.0%
$4.67+41.9%$3.29+33.2%$2.47+58.3%$1.56+69.6%$0.92-77.9%
EPS (basic)$4.81+41.5%$3.40+32.8%$2.56+59.0%$1.61+69.5%$0.95-78.3%
Weighted-avg shares (basic)99.5M-0.9%100M+2.8%97.7M+2.0%95.8M+1.3%94.6M+1.6%
Weighted-avg shares (diluted)103M-1.2%104M+2.7%101M+2.1%98.9M+1.0%97.9M+0.1%
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
2.52B+46.3%1.72B+7.3%1.61B+10.6%1.45B+49.4%973M-4.3%
Cash & equivalents713M+206.0%233M-7.2%251M-4.5%263M-22.9%341M+82.1%
Short-term investments
————371M-39.6%
Accounts receivable687M+43.4%479M+9.1%439M+25.5%350M+88.7%186M+18.1%
Inventory69.0M+20.2%57.4M+49.9%38.3M+9.1%35.1M+15.1%30.5M+8.9%
Prepaid expenses171M+252.0%48.5M———
Other current assets116M+82.1%63.6M-35.0%97.8M+23.6%79.1M+73.8%45.5M+51.2%
4.63B+24.5%3.72B+14.4%3.25B+37.3%2.37B+14.3%2.07B+19.5%
Property, plant & equipment89.8M+8.7%82.6M+16.7%70.8M+20.8%58.6M+0.0%58.6M+31.4%
Operating lease right-of-use455M-10.6%509M+84.2%277M+217.8%87.0M-10.5%97.2M+17.4%
Goodwill6.10M+7.0%5.70M-1.7%5.80M+7.4%5.40M0.00
Intangible assets4.70M-87.1%36.5M+2.8%35.5M-4.6%37.2M0.00
Long-term investments———299M-46.6%561M+146.9%
Deferred tax assets320M-34.1%486M+33.9%363M+18.5%306M-2.9%315M-1.3%
Other non-current assets48.7M-6.3%52.0M+4.8%49.6M+98.4%25.0M+468.2%4.40M-31.3%
743M+46.4%508M-22.5%655M+21.8%538M+118.8%246M+31.8%
Accrued liabilities674M+46.1%462M+2.9%449M+29.1%348M+53.9%226M+33.8%
Short-term & current debt—0.00-100.0%170M+0.4%169M0.00
Current lease liability56.0M+37.9%40.6M+26.9%32.0M+83.9%17.4M+5.5%16.5M+60.2%
Other current liabilities69.1M+49.9%46.1M+28.4%35.9M+73.4%20.7M+3.5%20.0M+12.4%
1.38B+22.1%1.13B+10.8%1.02B+54.2%661M-5.4%699M+14.8%
Long-term debt———0.00-100.0%335M+5.4%
Non-current lease liability415M-8.7%455M+76.2%258M+176.3%93.5M-11.2%105M+11.5%
Operating lease liability (total)471M-4.9%496M+70.8%290M+161.8%111M-8.9%122M+16.3%
Deferred tax liabilities
0.00————
Other non-current liabilities220M+32.2%166M+56.3%106M+257.9%29.7M+141.5%12.3M+26.8%
3.25B+25.6%2.59B+16.0%2.23B+30.7%1.71B+24.3%1.37B+22.0%
Preferred stock0.000.000.000.000.00
Common stock100K+0.0%100K+0.0%100K+0.0%100K+0.0%100K+0.0%
Additional paid-in capital2.79B+9.3%2.55B+7.2%2.38B+12.2%2.12B+5.5%2.01B+8.7%
Retained earnings448M+1433.2%29.2M+118.6%-157M+61.4%-407M+36.0%-636M+12.4%
Accumulated other comprehensive income13.1M+125.9%5.80M-17.1%7.00M+188.6%-7.90M-364.7%-1.70M-194.4%
Total equity incl. non-controlling3.25B+25.6%2.59B+16.0%2.23B+30.7%1.71B+24.3%1.37B+22.0%
Total liabilities & equity4.63B+24.5%3.72B+14.4%3.25B+37.3%2.37B+14.3%2.07B+19.5%
Common shares issued100M+0.7%99.4M+0.7%98.7M+2.3%96.5M+1.7%94.9M+1.5%
Common shares outstanding100M+0.7%99.4M+0.7%98.7M+2.3%96.5M+1.7%94.9M+1.5%
Shares outstanding (cover)100M+0.7%99.7M+0.2%99.5M+3.0%96.6M+1.4%95.2M+1.4%
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
783M+31.5%595M+52.7%390M+14.9%339M+32.3%257M+12.3%
Depreciation & amortization30.1M+11.1%27.1M+27.2%21.3M+36.5%15.6M+43.1%10.9M+26.7%
Intangible amortization4.10M+13.9%3.60M+2.9%3.50M+600.0%500K0.00
Share-based compensation218M+11.5%196M+0.6%194M+12.2%173M+29.0%134M+34.2%
Deferred income taxes164M+233.5%-123M-102.6%-60.7M-375.9%22.0M+300.0%5.50M+101.8%
Change in receivables211M+428.9%39.8M-55.4%89.3M-44.9%162M+471.1%28.4M-6.9%
Change in inventory15.3M-19.9%19.1M+453.7%-5.40M-307.7%2.60M+4.0%2.50M-76.6%
Other operating activities700K+600.0%100K-85.7%700K-56.3%1.60M+153.3%-3.00M-181.1%
-264M-108.5%-127M+72.9%-467M-163.7%-177M-36.0%-130M-3275.6%
Capital expenditure34.0M-11.0%38.2M+35.0%28.3M+71.5%16.5M-29.5%23.4M+114.7%
Free cash flow749M+34.4%557M+54.1%362M+12.0%323M+38.5%233M+7.1%
Acquisitions0.000.000.00-100.0%42.7M0.00
-38.3M+92.1%-487M-845.3%65.3M+127.9%-234M-955.1%27.4M+117.4%
Long-term debt issued0.000.000.000.000.00
Long-term debt repaid0.000.000.000.000.00
Common stock issued129M+6.0%122M+87.0%65.3M+46.1%44.7M+62.5%27.5M-5.5%
Common stock repurchased168M-44.1%300M0.000.000.00
Dividends paid0.000.000.000.000.00
FX effect on cash0.000.00-100.0%300K+123.1%-1.30M0.00
Net change in cash480M+2751.9%-18.1M-56.0%-11.6M+84.2%-73.3M-147.7%154M+105.5%
Interest paid0.00-100.0%1.60M-57.9%3.80M-42.4%6.60M-23.3%8.60M-25.9%
Income taxes paid81.4M-62.6%218M+322.3%51.5M+257.6%14.4M+182.4%5.10M-66.7%
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap14.2B+4.6%13.6B+4.8%12.9B+12.7%11.5B+42.1%8.08B-9.8%
P/E29.7×-25.4%39.8×-41.3%67.8×-65.6%197.3×+118.7%90.2×+310.0%
P/S5.0×-13.8%5.8×-20.6%7.3×-12.2%8.3×+16.0%7.1×-16.8%
P/B4.4×-16.7%5.2×-19.0%6.5×-13.0%7.4×+26.4%5.9×-26.1%
P/FCF19.0×-22.1%24.4×-27.6%33.7×-48.1%64.9×+87.1%34.7×-15.8%
Earnings yield3.4%+34.0%2.5%+70.5%1.5%+191.1%0.51%-54.3%1.1%-75.6%
FCF yield5.3%+28.4%4.1%+38.2%3.0%+92.8%1.5%-46.5%2.9%+18.8%
Source filing10-K10-K10-K10-K10-K
Fiscal yearCEOTotal, as reportedActually paidOther executives, average$100 in the stock$100 in peers
FY2025Kyle W. Gano, Ph.D$6.9M$6M$6.9M$147.97$124.75
FY2024Kevin C. Gorman, Ph.D $16M / $16.7MKyle W. Gano, Ph.D $8.5M / $7.1M$24.6M$23.8M$6.7M$142.41$93.49
FY2023Kevin C. Gorman, Ph.D$15.8M$12.3M$6.3M$137.46$94.03
FY2022Kevin C. Gorman, Ph.D$11.9M$21.9M$5.2M$124.61$89.90
FY2021Kevin C. Gorman, Ph.D$14.1M$4.5M$6.4M$88.86$100.02
FY2020Kevin C. Gorman, Ph.D$13.9M$8.2M$6.5M——

From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.

About this data

Source: NBIX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all NBIX filings on SEC EDGAR → Not investment advice.